Supportive Care and Use of Hematopoietic Growth Factors in Myelodysplastic Syndromes

Seminars in Hematology

Volumn 45, Issue 1, 2008, Pages 14-22

  Hellström Lindberg, Eva ^a   Malcovati, Luca ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DEFERASIROX; DEFEROXAMINE; ERYTHROPOIETIN; FAS ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; PLACEBO; REMIPLISTIM; THYMOCYTE ANTIBODY;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOPENIA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DNA METHYLATION; DRUG EFFICACY; HEALTH HAZARD; HEMATOPOIESIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IRON CHELATION; MONOCYTIC LEUKEMIA; MONOTHERAPY; MORTALITY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REFRACTORY ANEMIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SURVIVAL; THALASSEMIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANEMIA; COLONY-STIMULATING FACTORS; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; HEMATOPOIESIS; HUMANS; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; PROGNOSIS; THROMBOCYTOPENIA;

EID: 37549066376     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2007.10.004     Document Type: Article

References (79)

1. Cazzola M., and Malcovati L. Myelodysplastic syndromes-Coping with ineffective hematopoiesis. N Engl J Med 352 (2005) 536-538
2. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
3. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
4. Germing U., Gattermann N., Strupp C., Aivado M., and Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: A retrospective analysis of 1600 patients. Leuk Res 24 (2000) 983-992
5. Malcovati L., Della Porta M., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria. A basis for clinical decision-making. J Clin Oncol 23 (2005) 7594-7603
6. Howe R.B., Porwit-MacDonald A., Wanat R., Tehranchi R., and Hellstrom-Lindberg E. The WHO classification of MDS does make a difference. Blood 103 (2004) 3265-3270
7. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
8. de Witte T., Suciu S., Verhoef G., Labar B., Archimbaud E., Aul C., et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 98 (2001) 2326-2331
9. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Invernizzi R., Giagounidis A., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25 (2007) 3503-3510
10. Bowen D.T., and Hellstrom-Lindberg E. Treatment of anemia in myelodysplastic syndromes. In: Bennet J.M. (Ed). The Myelodysplastic Syndromes in Pathobiology and Clinical Management (2002), Marcel Dekker, New York, NY 345-372
11. Maschek H., Kaloutsi V., Rodriguez-Kaiser M., Werner M., Choritz H., Mainzer K., et al. Hypoplastic myelodysplastic syndrome: Incidence, morphology, cytogenetics, and prognosis. Ann Hematol 66 (1993) 117-122
12. Vander Heiden M.G., and Thompson C.B. Bcl-2 proteins: Regulators of apoptosis or of mitochondrial homeostasis?. Nat Cell Biol 1 (1999) E209-E216
13. Wajant H. The Fas signaling pathway: More than a paradigm. Science 296 (2002) 1635-1636
14. De Maria R., Testa U., Luchetti L., Zeuner A., Stassi G., Pelosi E., et al. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood 93 (1999) 796-803
15. Claessens Y.E., Bouscary D., Dupont J.M., Picard F., Melle J., Gisselbrecht S., et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: Evidence for Fas-dependent apoptosis. Blood 99 (2002) 1594-1601
16. Claessens Y.E., Park S., Dubart-Kupperschmitt A., Mariot V., Garrido C., Chretien S., et al. Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD. Blood 105 (2005) 4035-4042
17. Tehranchi R., Fadeel B., Forsblom A.M., Christensson B., Samuelsson J., Zhivotovsky B., et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 101 (2003) 1080-1086
18. Tehranchi R., Invernizzi R., Grandien A., Zhivotovsky B., Fadeel B., Forsblom A.M., et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 106 (2005) 247-253
19. Bouscary D., De Vos J., Guesnu M., Jondeau K., Viguier F., Melle J., et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 11 (1997) 839-845
20. Verhoef G.E., De Schouwer P., Ceuppens J.L., Van Damme J., Goossens W., and Boogaerts M.A. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 6 (1992) 1268-1272
21. Otsuki T., Nagakura S., Wang J., Bloom M., Grompe M., and Liu J.M. Tumor necrosis factor-alpha and CD95 ligation suppress erythropoiesis in Fanconi anemia C gene knockout mice. J Cell Physiol 179 (1999) 79-86
22. Hellstrom-Lindberg E., Schmidt-Mende J., Forsblom A.M., Christensson B., Fadeel B., and Zhivotovsky B. Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol 112 (2001) 714-726
23. Sakura T., Murakami H., Saitoh T., Naruse T., and Tsuchiya J. Ultrastructural abnormalities of bone marrow erythroblasts in refractory anemia. Ultrastruct Pathol 22 (1998) 173-180
24. van de Loosdrecht A.A., Brada S.J., Blom N.R., Hendriks D.W., Smit J.W., van den Berg E., et al. Mitochondrial disruption and limited apoptosis of erythroblasts are associated with high risk myelodysplasia. An ultrastructural analysis. Leuk Res 25 (2001) 385-393
25. Gattermann N., Wulfert M., Junge B., Germing U., Haas R., and Hofhaus G. Ineffective hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome. Blood 103 (2004) 1499-1502
26. Shin M.G., Kajigaya S., Levin B.C., and Young N.S. Mitochondrial DNA mutations in patients with myelodysplastic syndromes. Blood 101 (2003) 3118-3125
27. Cazzola M., Invernizzi R., Bergamaschi G., Levi S., Corsi B., Travaglino E., et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 101 (2003) 1996-2000
28. Della Porta M.G., Malcovati L., Gallì A., Boggi S., Travaglino E., Marseglia C., et al. Mitochondrial ferritin expression and clonality of hematopoiesis in patients with refractory anemia with ringed sideroblasts. Blood 106 (2005) 3444
29. Barrett J., Saunthararajah Y., and Molldrem J. Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology?. Semin Hematol 37 (2000) 15-29
30. Saunthararajah Y., Nakamura R., Nam J.M., Robyn J., Loberiza F., Maciejewski J.P., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100 (2002) 1570-1574
31. Molldrem J.J., Caples M., Mavroudis D., Plante M., Young N.S., and Barrett A.J. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 99 (1997) 699-705
32. Daskalakis M., Nguyen T.T., Nguyen C., Guldberg P., Kohler G., Wijermans P., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 100 (2002) 2957-2964
33. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 20 (2002) 2429-2440
34. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106 (2006) 1794-1803
35. Saunthararajah Y., Hillery C.A., Lavelle D., Molokie R., Dorn L., Bressler L., et al. Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 102 (2003) 3865-3870
36. Aguayo A. The role of angiogenesis in the biology and therapy of myelodysplastic syndromes. Curr Hematol Rep 3 (2004) 184-191
37. Panoskaltsis N. Dendritic cells in MDS and AML-Cause, effect or solution to the immune pathogenesis of disease?. Leukemia 19 (2005) 354-357
38. + marrow progenitors from MDS patients with high levels of intramedullary apoptosis have reduced expression of alpha4beta1 and alpha5beta1 integrins. Leukemia 19 (2005) 57-63
39. Kiladjian J.J., Bourgeois E., Lobe I., Braun T., Visentin G., Bourhis J.H., et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 20 (2006) 463-470
40. Izaks G.J., Westendorp R.G., and Knook D.L. The definition of anemia in older persons. JAMA 281 (1999) 1714-1717
41. Penninx B.W., Guralnik J.M., Onder G., Ferrucci L., Wallace R.B., and Pahor M. Anemia and decline in physical performance among older persons. Am J Med 115 (2003) 104-110
42. Jansen A.J., Essink-Bot M.L., Beckers E.A., Hop W.C., Schipperus M.R., and Van Rhenen D.J. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol 121 (2003) 270-274
43. Alessandrino E.P., Amadori S., Barosi G., Cazzola M., Grossi A., Liberato L.N., et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 87 (2002) 1286-1306
44. Bowen D., Culligan D., Jowitt S., Kelsey S., Mufti G., Oscier D., et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 120 (2003) 187-200
45. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., Ahlgren T., Dahl I.M., Dybedal I., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life. Br J Haematol 120 (2003) 1037-1046
46. Armand P., Kim H.T., Cutler C.S., Ho V.T., Koreth J., Alyea E., et al. Prognostic impact of elevated pre-transplant serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109 (2007) 4586-4588
47. Angelucci E., Muretto P., Nicolucci A., Baronciani D., Erer B., Gaziev J., et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 100 (2002) 17-21
48. Franchini M., Gandini G., de Gironcoli M., Vassanelli A., Borgna-Pignatti C., and Aprili G. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood 95 (2000) 2776-2779
49. Cappellini M.D., Cohen A., Piga A., Bejaoui M., Perrotta S., Agaoglu L., et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107 (2006) 3455-3462
50. Testa U. Apoptotic mechanisms in the control of erythropoiesis. Leukemia 18 (2004) 1176-1199
51. Hellstrom E., Birgegard G., Lockner D., Helmers C., Ost A., and Wide L. Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Eur J Haematol 47 (1991) 355-360
52. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies. Br J Haematol 89 (1995) 67-71
53. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 103 (1998) 1070-1074
54. Hellstrom-Lindberg E., Negrin R., Stein R., Krantz S., Lindberg G., Vardiman J., et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 99 (1997) 344-351
55. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96 (2000) 3671-3674
56. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108 (2006) 419-425
57. Terpos E., Mougiou A., Kouraklis A., Chatzivassili A., Michalis E., Giannakoulas N., et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: A phase II trial in 281 patients. Br J Haematol 118 (2002) 174-180
58. Verhoef G., Van den Berghe H., and Boogaerts M. Cytogenetic effects on cells derived from patients with myelodysplastic syndromes during treatment with hemopoietic growth factors. Leukemia 6 (1992) 766-769
59. Rigolin G.M., Porta M.D., Ciccone M., Bugli A.M., Bragotti L.Z., Mauro E., et al. In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells. Br J Haematol 126 (2004) 501-507
60. Ljung T., Back R., and Hellstrom-Lindberg E. Hypochromic red blood cells in low-risk myelodysplastic syndromes: Effects of treatment with hemopoietic growth factors. Haematologica 89 (2004) 1446-1453
61. Bennett C.L., Luminari S., Nissenson A.R., Tallman M.S., Klinge S.A., McWilliams N., et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 351 (2004) 1403-1408
62. Mannone L., Gardin C., Quarre M.C., Bernard J.F., Vassilieff D., Ades L., et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 133 (2006) 513-519
63. Musto P., Lanza F., Balleari E., Grossi A., Falcone A., Sanpaolo G., et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 128 (2005) 204-209
64. Stasi R., Abruzzese E., Lanzetta G., Terzoli E., and Amadori S. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 16 (2005) 1921-1927
65. Osterborg A., Steegmann J.L., Hellmann A., Couban S., Mayer J., and Eid J.E. Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy. Br J Haematol 136 (2007) 736-744
66. Dmoszynska A., Kloczko J., Rokicka M., Hellmann A., Spicka I., and Eid J.E. A dose exploration, phase I/II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy. Haematologica 92 (2007) 493-501
67. Negrin R.S., Stein R., Doherty K., Cornwell J., Vardiman J., Krantz S., et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy. Blood 87 (1996) 4076-4081
68. Hellstrom-Lindberg E., Ahlgren T., Beguin Y., Carlsson M., Carneskog J., Dahl I.M., et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: Results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92 (1998) 68-75
69. Casadevall N., Durieux P., Dubois S., Hemery F., Lepage E., Quarre M.C., et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial. Blood 104 (2004) 321-327
70. Balleari E., Rossi E., Clavio M., Congiu A., Gobbi M., Grosso M., et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: Results from a randomized single-centre study. Ann Hematol 85 (2006) 174-180
71. Remacha A.F., Arrizabalaga B., Villegas A., Manteiga R., Calvo T., Julia A., et al., The Spanish Erythropathology Group. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. Haematologica 84 (1999) 1058-1064
72. Bowen D., Hyslop A., Keenan N., Groves M., Culligan D., Johnson P., et al. Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia. Haematologica 91 (2006) 709-710
73. Henke M., Laszig R., Rube C., Schafer U., Haase K.D., Schilcher B., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
74. Temkin S.M., Hellmann M., Serur E., Lee Y.C., and Abulafia O. Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation. Int J Gynecol Cancer 16 (2006) 1855-1861
75. Leyland-Jones B., Semiglazov V., Pawlicki M., Pienkowski T., Tjulandin S., Manikhas G., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 23 (2005) 5960-5972
76. Jadersten M., Montgomery S.M., Dybedal I., Porwit-MacDonald A., and Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 106 (2005) 803-811
77. Jädersten M., Malcovati L., Dybedal I., Della Porta M., Invernizzi R., Montgomery S., et al. Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need. Blood 106 (2006) 172 (abstr)
78. Kaushansky K., Lok S., Holly R.D., Broudy V.C., Lin N., Bailey M.C., et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 369 (1994) 568-571
79. Newland A., Caulier M.T., Kappers-Klunne M., Schipperus M.R., Lefrere F., Zwaginga J.J., et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 135 (2006) 547-553